China Daily Briefing

BABA +5.99% to $121.86 was the session headline, but the more analytically interesting data point is that Tencent (TCEHY) fell -3.61% on the same day. When BABA, BIDU, TCOM, FUTU, and IQ all run hard and Tencent specifically doesn't, the historical pattern points to either regulatory asymmetry — Alibaba having cleared more of its SAMR overhang versus Tencent still carrying gaming + social platform regulatory uncertainty — or an earnings/guidance revision that hit Tencent but not the travel and search names. Alibaba's travel arm (Fliggy, via Ctrip/TCOM adjacency) is likely benefiting from the same domestic travel demand thesis as TCOM +4.76%. The A/H premium for Alibaba has been compressing, meaning HK-listed 9988.HK and the US ADR (BABA) are converging — a sign Southbound Stock Connect buyers may be driving the mainland bid. FUTU +4.23% to $99.12 is notable — the Hong Kong-based online broker benefits from cross-border capital interest, suggesting retail investor participation in the China platform rally is broadening beyond institutional flows.

Trip.com (TCOM) +4.76% to $44.47 led the Travel sector to the session's top gain at +4.76%. This isn't just a travel stock move — it's a signal about the state of China's domestic consumption recovery. TCOM's model (hotel bookings, flight ticketing, package tours) is one of the most direct proxies for Chinese middle-class discretionary spending, and a +4.76% session move implies the market is pricing in continued outbound/domestic travel demand despite the macro headwinds. China's drug innovation data released today adds a complementary narrative: domestically produced novel drugs accounting for over 80% of market approvals in H1 2026 reflects a 'systemic leap' in innovation quality that the market is beginning to value beyond the NDRC-heavy industrial complex. The Education sector +1.58% (a year ago these were uninvestable under the for-profit crackdown) shows regulatory sentiment has genuinely shifted — the platform names that survived 2021-2023 regulatory pressure are now being re-rated as normalized businesses, not regulatory targets.

KE Holdings (BEKE) -1.72% to $17.10 and Property/Real Estate sector -1.72% were the session's only meaningful losers. This matters because BEKE is both the property sector proxy and a data point about secondary home market activity in China. While the platform/travel names recovered strongly, property transaction velocity hasn't. Country Garden's restructuring overhang and Vanke's balance sheet concerns remain unresolved — NDRC policy signals on developer support have been incremental, not transformative. The A/H premium dynamic is starkest here: Mainland A-share property names may have performed differently than the US-listed BEKE, but the US ADR is the offshore signal and it's telling you that property is still structurally challenged even as the broader PBOC liquidity backdrop improves. XPEV -0.59% was the other loser — EV sector gaining only +0.57% on a day when travel ran +4.76% suggests China's EV competitive intensity (BYD Hungary investigation, pricing wars) is tempering the enthusiasm that would otherwise flow from domestic consumption optimism. Watch PBOC's next MLF operation for clues on whether liquidity support will extend to property developers.